Anupam Rasayan cuts EBITDA margin guidance by 200 bps, flags consolidation drag
Management now expects an EBITDA margin of 23-24% for FY26, down from 25%, citing the Bliss GVS Pharma consolidation and phasing effects. The ₹14,000 crore order book underpins a 20-30% annual growth outlook.
— 1 earlier story on Anupam Rasayan India Ltd. →What's new
- Anupam Rasayan cut its EBITDA margin guidance to 23-24% from 25%.
- The order book stands at ₹14,000 crore, providing visibility for 20-30% annual revenue growth over 3-5 years.
- The Bliss GVS Pharma acquisition is central to its push for a vertically integrated pharma platform.
Why this matters
A 200 bps margin cut on a call where the headline story was supposed to be growth and integration tells you where the friction is: bringing Bliss GVS in-house is costing near-term profitability. The large order book buys the company time to execute, but the margin trade-off is now explicit.
What we're watching
- The pace of Bliss GVS integration and whether it becomes margin-accretive.
- Whether the 20-30% growth rate holds against the newly consolidated base.
- Next quarter's margins to confirm the phasing explanation.
The full read
Anupam Rasayan's May 2026 concall delivered two messages. First, growth: a ₹14,000 crore order book that the company says underpins a 20-30% annual revenue growth trajectory for 3-5 years. Second, the cost of that growth: EBITDA margin guidance was cut to 23-24% from 25%, a 200 bps reduction management blamed on consolidating its Bliss GVS Pharma acquisition and normal business phasing. The acquisition is the company's bid to build a vertically integrated pharma CDMO. The margin guidance revision is the market's first hard look at the integration's P&L impact. For now, the order book provides cover. The test is whether the consolidated entity can grow into that book without further margin erosion.
Questions answered
- Why did Anupam Rasayan lower its EBITDA margin guidance?
- The company cited two factors: the consolidation effects from integrating Bliss GVS Pharma and phasing across its business cycle. The guidance was reduced by 200 basis points from a prior expectation of 25%.
- How large is the order book and what growth does it imply?
- The order book is ₹14,000 crore, which management says gives visibility for 20-30% annual revenue growth over the next three to five years.
- What is the strategic role of the Bliss GVS Pharma deal?
- The acquisition is positioned to build a vertically integrated pharmaceutical contract development and manufacturing organization (CDMO) platform. It is a key part of the company's long-term strategy.
- Is the margin guidance cut permanent?
- The filing does not specify. It attributes the cut to current consolidation effects and business phasing, leaving open whether margins will recover to prior levels once integration is complete.
Anupam Rasayan India Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ANURAS →- 25 May 2026 · 6:48 PM IST Anupam Rasayan cuts EBITDA margin guidance by 200 bps, flags consolidation drag
- 25d ago Anupam Rasayan scores a global first in ETFA production